PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
MammaPrint + BluePrint predict pCR after NCT-FLEX, O’Shaughnessy et al., SABCS 2023 Abstract
SABCS 2023, PO5-15-04 Authors: O'Shaughnessy et al.
Read MoreRacial Disparities in HR+HER2- ESBC, Reid et al., SABCS 2023 Abstract
SABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreRacial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreMammaPrint UltraLow from FLEX Study, Graham et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-11 Authors: Cathy Graham et al.
Read MoreHER2-low in the FLEX Study, Sivapiragasam et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-02 Authors: Sivapiragasam et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreMINDACT & TAILORx Exploratory Comparison, Neven et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-05 Authors: Patrick Neven et al.
Read More
